rhErythropoietin-b as a tissue protective agent in kidney transplantation: A pilot randomized controlled trial

BMC Research Notes

Volumn 8, Issue 1, 2015, Pages

  Coupes, Beatrice ^a   De Freitas, Declan G ^a   Roberts, Stephen A ^b   Read, Ian ^a   Riad, Hany ^a   Brenchley, Paul E C ^a   Picton, Michael L ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Delayed graft function; Erythropoietin; Ischaemia reperfusion

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; CREATININE; ERYTHROPOIETIN; HAVCR1 PROTEIN, HUMAN; INTERLEUKIN 18; LCN2 PROTEIN, HUMAN; LIPOCALIN; MEMBRANE PROTEIN; ONCOPROTEIN; PROTECTIVE AGENT; VIRUS RECEPTOR;

AGED; BLOOD; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DONOR; DOUBLE BLIND PROCEDURE; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOLOGY; KIDNEY; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SURGERY; URINE;

ACUTE-PHASE PROTEINS; AGED; BIOMARKERS; CREATININE; DELAYED GRAFT FUNCTION; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; GRAFT REJECTION; HUMANS; INTERLEUKIN-18; KIDNEY; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIPOCALINS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PILOT PROJECTS; PROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS; RECEPTORS, VIRUS; TISSUE DONORS;

EID: 84924267611     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/s13104-014-0964-0     Document Type: Article

References (35)

1. NHS Blood and Transplant Annual Report. 2012. http://www.odt.nhs.uk/uk-transplant-registry/annual-activity-report.
2. Port FK, Bragg-Gresham JL, Metzger RA, Dykstra DM, Gillespie BW, Young EW, et al. Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors. Transplantation. 2002;74:1281-6.
3. Leichtman AB, Cohen D, Keith D, O'Connor K, Goldstein M, McBride V, et al. Kidney and pancreas transplantation in the United States, 1997-2006: the HRSA Breakthrough Collaboratives and the 58 DSA Challenge. Am J Transplant. 2008;8(4 Pt 2):946-57.
4. Moreno F, Sanz-Guajardo D, López-Gómez JM, Jofre R, Valderrábano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol. 2000;11:335-42.
5. Bárány P, Pettersson E, Bergström J. Erythropoietin treatment improves quality of life in hemodialysis patients. Scand J Urol Nephrol Suppl. 1990;131:55-60.
6. Ishii Y, Sawada T, Murakami T, Sakuraoka Y, Shiraki T, Shimizu A, et al. Renoprotective effect of erythropoietin against ischaemia-reperfusion injury in a non-human primate model. Nephrol Dial Transplant. 2011;26:1157-62.
7. Forman CJ, Johnson DW, Nicol DL. Erythropoietin administration protects against functional impairment and cell death after ischaemic renal injury in pigs. BJU Int. 2007;99:162-5.
8. Lee SH, Li C, Lim SW, Ahn KO, Choi BS, Kim YS, et al. Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol. 2005;25:64-76.
9. Yang CW, Li C, Jung JY, Shin SJ, Choi BS, Lim SW, et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney 2. FASEB J. 2003;17:1754-5. 1530-6860 (Electronic).
10. Patel NS, Sharples EJ, Cuzzocrea S, Chatterjee PK, Britti D, Yaqoob MM, et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo 1. Kidney Int. 2004;66:983-9. 0085-2538 (Print).
11. Abdelrahman M, Sharples EJ, McDonald MC, Collin M, Patel NSA, Yaqoob MM, et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock. 2004;22:63-9.
12. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol. 2004;15:2115-24.
13. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495-505.
14. ®: 4-4.
15. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14:2534-43.
16. Mishra J, Mori K, Ma Q, Kelly C, Yang J, Mitsnefes M, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2004;15:3073-82.
17. Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol. 2005;16:3046-52.
18. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem. 1998;273:4135-42.
19. Vaidya VS, Ozer JS, Dieterle F, Collings FB, Ramirez V, Troth S, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol. 2010;28:478-85.
20. Sureshkumar KK, Hussain SM, Ko TY, Thai NL, Marcus RJ. Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial. Clin J Am Soc Nephrol. 2012;7:1498-506.
21. Hafer C, Becker T, Kielstein JT, Bahlmann E, Schwarz A, Grinzoff N, et al. High-dose erythropoietin has no effect on short- or long-term graft function following deceased donor kidney transplantation. Kidney Int. 2012;81:314-20.
22. Martinez F, Kamar N, Pallet N, Lang P, Durrbach A, Lebranchu Y, et al. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. Am J Transplant. 2010;10:1695-700.
23. Aydin Z, Mallat MJK, Schaapherder A FM, Van Zonneveld A J, Van Kooten C, Rabelink TJ, et al. Randomized trial of short-course high-dose erythropoietin in donation after cardiac death kidney transplant recipients. Am J Transplant. 2012;12:1793-800.
24. Roche Products Ltd. Neorecormin summary of product characteristics. 2010.
25. Krzyzanski W, Wyska E. Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:637-45.
26. Mohiuddin MK, El-Asir L, Gupta A, Brown A, Torpey N, Ward M, et al. Perioperative erythropoietin efficacy in renal transplantation. Transplant Proc. 2006;39:132-4.
27. Song YR, Lee T, You SJ, Chin HJ, Chae D-W, Lim C, et al. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol. 2009;30:253-60.
28. Poulsen TD, Andersen LW, Steinbrüchel D, Gøtze JP, Jørgensen OS, Olsen NV. Two large preoperative doses of erythropoietin do not reduce the systemic inflammatory response to cardiac surgery. J Cardiothorac Vasc Anesth. 2009;23:316-23.
29. Kamar N, Reboux AH, Cointault O, Esposito L, Cardeau-Desangles I, Lavayssiere L, et al. Impact of very early high doses of recombinant erythropoietin on anemia and allograft function in de novo kidney-transplant patients 1. Transpl Int. 2010;23:277-84. 1432-2277 (Electronic).
30. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke 2. Stroke. 2009;40:e647-56. 1524-4628 (Electronic).
31. Prunier F, Bière L, Gilard M, Boschat J, Mouquet F, Bauchart J-J, et al. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial. Am Heart J. 2012;163:200-7. e1.
32. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152:726-32.
33. Johnston O, O'kelly P, Spencer S, Donohoe J, Walshe JJ, Little DM, et al. Reduced graft function (with or without dialysis) vs immediate graft function-a comparison of long-term renal allograft survival 1. Nephrol Dial Transplant. 2006;21:2270-4. 0931-0509 (Print).
34. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. JEval Clin Pract. 2004;10:307-12. 1356-1294 (Print).
35. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. URL http://www.R-project.org/.